Ignite Creation Date:
2025-12-24 @ 9:59 PM
Ignite Modification Date:
2026-01-05 @ 5:25 PM
Study NCT ID:
NCT02750332
Status:
COMPLETED
Last Update Posted:
2017-03-15
First Post:
2016-04-21
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Bioavailability Food-Effect Study of an Oral Nitisinone Formulation to Treat Hereditary Tyrosinemia (HT-1)
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D020176', 'term': 'Tyrosinemias'}], 'ancestors': [{'id': 'D020739', 'term': 'Brain Diseases, Metabolic, Inborn'}, {'id': 'D001928', 'term': 'Brain Diseases, Metabolic'}, {'id': 'D001927', 'term': 'Brain Diseases'}, {'id': 'D002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D000592', 'term': 'Amino Acid Metabolism, Inborn Errors'}, {'id': 'D008661', 'term': 'Metabolism, Inborn Errors'}, {'id': 'D030342', 'term': 'Genetic Diseases, Inborn'}, {'id': 'D009358', 'term': 'Congenital, Hereditary, and Neonatal Diseases and Abnormalities'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C077073', 'term': 'nitisinone'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'james.price@cyclepharma.com', 'phone': '+44 1223 803638', 'title': 'James Price', 'organization': 'Cycle Pharmaceuticals Ltd'}, 'certainAgreement': {'piSponsorEmployee': False, 'restrictiveAgreement': False}}, 'adverseEventsModule': {'timeFrame': 'Adverse event data were collected over the period of the study (November 2015 - December 2015).', 'description': '20 subjects were entered in to the study and randomized to either fasted or fed treatment sequence before first administration of the Investigational Medicinal Product (IMP). One subject withdrew from the study after Treatment Period 1 (Fasted) due to personal reasons. As a result, only 19 subjects completed the fed treatment.', 'eventGroups': [{'id': 'EG000', 'title': 'Test Product (Fasted)', 'description': 'A single oral dose of Nitisinone 10 mg Tablet will be administered under fasted conditions.', 'otherNumAtRisk': 20, 'otherNumAffected': 0, 'seriousNumAtRisk': 20, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': 'Test Product (Fed)', 'description': 'A single oral dose of Nitisinone 10 mg Tablet will be administered under fed conditions.', 'otherNumAtRisk': 19, 'otherNumAffected': 2, 'seriousNumAtRisk': 19, 'seriousNumAffected': 0}], 'otherEvents': [{'term': 'Dizziness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 19, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Itching Throat', 'stats': [{'groupId': 'EG000', 'numAtRisk': 20, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 19, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}], 'frequencyThreshold': '0'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Maximum Observed Plasma Concentration (Cmax)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Test Product (Fasted)', 'description': 'A single oral dose of Nitisinone 10 mg Tablet will be administered under fasted conditions.'}, {'id': 'OG001', 'title': 'Test Product (Fed)', 'description': 'A single oral dose of Nitisinone 10 mg Tablet will be administered under fed conditions.'}], 'classes': [{'categories': [{'measurements': [{'value': '1168.23', 'spread': '22.2', 'groupId': 'OG000'}, {'value': '1054.32', 'spread': '15.6', 'groupId': 'OG001'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': '0 - 120 hours post-dose', 'unitOfMeasure': 'ng/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'All subjects for whom the primary PK parameters Cmax and AUC(0-120) could be calculated for at least 2 treatment periods (where one of the treatment periods is the Reference product), and who had no major protocol deviations thought to impact on the analysis of the PK data were included in the statistical PK analysis for the study.'}, {'type': 'PRIMARY', 'title': 'Area Under the Plasma Concentration Versus Time Curve (AUC(0-120))', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Test Product (Fasted)', 'description': 'A single oral dose of Nitisinone 10 mg Tablet will be administered under fasted conditions.'}, {'id': 'OG001', 'title': 'Test Product (Fed)', 'description': 'A single oral dose of Nitisinone 10 mg Tablet will be administered under fed conditions.'}], 'classes': [{'categories': [{'measurements': [{'value': '71441.92', 'spread': '26.4', 'groupId': 'OG000'}, {'value': '67242.59', 'spread': '17.1', 'groupId': 'OG001'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': '0 - 120 hours post-dose', 'unitOfMeasure': 'hr*ng/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'All subjects for whom the primary PK parameters Cmax and AUC(0-120) could be calculated for at least 2 treatment periods (where one of the treatment periods is the Reference product), and who had no major protocol deviations thought to impact on the analysis of the PK data were included in the statistical PK analysis for the study.'}, {'type': 'SECONDARY', 'title': 'Area Under the Plasma Concentration Versus Time Curve (AUC(0-72))', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Test Product (Fasted)', 'description': 'A single oral dose of Nitisinone 10 mg Tablet will be administered under fasted conditions.'}, {'id': 'OG001', 'title': 'Test Product (Fed)', 'description': 'A single oral dose of Nitisinone 10 mg Tablet will be administered under fed conditions.'}], 'classes': [{'categories': [{'measurements': [{'value': '52976.29', 'spread': '24.0', 'groupId': 'OG000'}, {'value': '49762.02', 'spread': '17.5', 'groupId': 'OG001'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': '0 - 72 hours post-dose', 'unitOfMeasure': 'hr*ng/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'All subjects for whom the primary PK parameters Cmax and AUC(0-120) could be calculated for at least 2 treatment periods (where one of the treatment periods is the Reference product), and who had no major protocol deviations thought to impact on the analysis of the PK data were included in the statistical PK analysis for the study.'}, {'type': 'SECONDARY', 'title': 'Area Under the Plasma Concentration Versus Time Curve, With Extrapolation to Infinity (AUC(0-∞))', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Test Product (Fasted)', 'description': 'A single oral dose of Nitisinone 10 mg Tablet will be administered under fasted conditions.'}, {'id': 'OG001', 'title': 'Test Product (Fed)', 'description': 'A single oral dose of Nitisinone 10 mg Tablet will be administered under fed conditions.'}], 'classes': [{'categories': [{'measurements': [{'value': '100007.01', 'spread': '34.5', 'groupId': 'OG000'}, {'value': '90749.55', 'spread': '19.3', 'groupId': 'OG001'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': '0 - 120 hours post-dose', 'unitOfMeasure': 'hr*ng/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'All subjects for whom the primary PK parameters Cmax and AUC(0-120) could be calculated for at least 2 treatment periods (where one of the treatment periods is the Reference product), and who had no major protocol deviations thought to impact on the analysis of the PK data were included in the statistical PK analysis for the study.'}, {'type': 'SECONDARY', 'title': 'Time to Maximum Observed Plasma Concentration (Tmax)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Test Product (Fasted)', 'description': 'A single oral dose of Nitisinone 10 mg Tablet will be administered under fasted conditions.'}, {'id': 'OG001', 'title': 'Test Product (Fed)', 'description': 'A single oral dose of Nitisinone 10 mg Tablet will be administered under fed conditions.'}], 'classes': [{'categories': [{'measurements': [{'value': '3.00', 'groupId': 'OG000', 'lowerLimit': '2.00', 'upperLimit': '8.00'}, {'value': '6.00', 'groupId': 'OG001', 'lowerLimit': '2.00', 'upperLimit': '10.00'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': '0 - 120 hours post-dose', 'unitOfMeasure': 'hr', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED', 'populationDescription': 'All subjects for whom the primary PK parameters Cmax and AUC(0-120) could be calculated for at least 2 treatment periods (where one of the treatment periods is the Reference product), and who had no major protocol deviations thought to impact on the analysis of the PK data were included in the statistical PK analysis for the study.'}, {'type': 'SECONDARY', 'title': 'Terminal Elimination Rate Constant (λz)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Test Product (Fasted)', 'description': 'A single oral dose of Nitisinone 10 mg Tablet will be administered under fasted conditions.'}, {'id': 'OG001', 'title': 'Test Product (Fed)', 'description': 'A single oral dose of Nitisinone 10 mg Tablet will be administered under fed conditions.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.011', 'spread': '26.9', 'groupId': 'OG000'}, {'value': '0.012', 'spread': '15.7', 'groupId': 'OG001'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': '0 - 120 hours post-dose', 'unitOfMeasure': '1/hr', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'All subjects for whom the primary PK parameters Cmax and AUC(0-120) could be calculated for at least 2 treatment periods (where one of the treatment periods is the Reference product), and who had no major protocol deviations thought to impact on the analysis of the PK data were included in the statistical PK analysis for the study.'}, {'type': 'SECONDARY', 'title': 'Apparent Terminal Elimination Half-life (t1/2)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Test Product (Fasted)', 'description': 'A single oral dose of Nitisinone 10 mg Tablet will be administered under fasted conditions.'}, {'id': 'OG001', 'title': 'Test Product (Fed)', 'description': 'A single oral dose of Nitisinone 10 mg Tablet will be administered under fed conditions.'}], 'classes': [{'categories': [{'measurements': [{'value': '64.40', 'spread': '26.9', 'groupId': 'OG000'}, {'value': '59.22', 'spread': '15.7', 'groupId': 'OG001'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': '0 - 120 hours post-dose', 'unitOfMeasure': 'hr', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'All subjects for whom the primary PK parameters Cmax and AUC(0-120) could be calculated for at least 2 treatment periods (where one of the treatment periods is the Reference product), and who had no major protocol deviations thought to impact on the analysis of the PK data were included in the statistical PK analysis for the study.'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Treatment Sequence A (Fed) - B (Fasted)', 'description': 'Subjects will receive a single 10 mg tablet of Nitisinone in treatment period 1 under fed conditions, and 10 mg tablet of Nitisinone in treatment period 2 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.\n\nNitisinone: A single oral dose of Nitisinone 10 mg Tablet will be administered.'}, {'id': 'FG001', 'title': 'Treatment Sequence B (Fasted) - A (Fed)', 'description': 'Subjects will receive a single 10 mg tablet of Nitisinone in treatment period 1 under fasting conditions, and 10 mg tablet of Nitisinone in treatment period 2 under fed conditions. Each treatment period will be separated by at least 23 calendar days of washout period.\n\nNitisinone: A single oral dose of Nitisinone 10 mg Tablet will be administered.'}], 'periods': [{'title': 'Treatment Period 1', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '10'}, {'groupId': 'FG001', 'numSubjects': '10'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '10'}, {'groupId': 'FG001', 'numSubjects': '9'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}]}], 'dropWithdraws': [{'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}]}]}, {'title': 'Treatment Period 2', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '10'}, {'groupId': 'FG001', 'numSubjects': '9'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '10'}, {'groupId': 'FG001', 'numSubjects': '9'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}]}]}]}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'BG000'}]}], 'groups': [{'id': 'BG000', 'title': 'All Study Participants'}], 'measures': [{'title': 'Age, Categorical', 'classes': [{'categories': [{'title': '<=18 years', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}, {'title': 'Between 18 and 65 years', 'measurements': [{'value': '20', 'groupId': 'BG000'}]}, {'title': '>=65 years', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '3', 'groupId': 'BG000'}]}, {'title': 'Male', 'measurements': [{'value': '17', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race/Ethnicity, Customized', 'classes': [{'title': 'Black', 'categories': [{'measurements': [{'value': '18', 'groupId': 'BG000'}]}]}, {'title': 'Caucasian', 'categories': [{'measurements': [{'value': '2', 'groupId': 'BG000'}]}]}], 'paramType': 'NUMBER', 'unitOfMeasure': 'Participants'}, {'title': 'Region of Enrollment', 'classes': [{'title': 'South Africa', 'categories': [{'measurements': [{'value': '20', 'groupId': 'BG000'}]}]}], 'paramType': 'NUMBER', 'unitOfMeasure': 'participants'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'BASIC_SCIENCE', 'interventionModel': 'CROSSOVER'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 20}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2015-11'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2017-02', 'completionDateStruct': {'date': '2016-01', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2017-02-06', 'studyFirstSubmitDate': '2016-04-21', 'resultsFirstSubmitDate': '2016-10-19', 'studyFirstSubmitQcDate': '2016-04-21', 'lastUpdatePostDateStruct': {'date': '2017-03-15', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2016-10-19', 'studyFirstPostDateStruct': {'date': '2016-04-25', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2016-12-13', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2015-12', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Maximum Observed Plasma Concentration (Cmax)', 'timeFrame': '0 - 120 hours post-dose'}, {'measure': 'Area Under the Plasma Concentration Versus Time Curve (AUC(0-120))', 'timeFrame': '0 - 120 hours post-dose'}], 'secondaryOutcomes': [{'measure': 'Area Under the Plasma Concentration Versus Time Curve (AUC(0-72))', 'timeFrame': '0 - 72 hours post-dose'}, {'measure': 'Area Under the Plasma Concentration Versus Time Curve, With Extrapolation to Infinity (AUC(0-∞))', 'timeFrame': '0 - 120 hours post-dose'}, {'measure': 'Time to Maximum Observed Plasma Concentration (Tmax)', 'timeFrame': '0 - 120 hours post-dose'}, {'measure': 'Terminal Elimination Rate Constant (λz)', 'timeFrame': '0 - 120 hours post-dose'}, {'measure': 'Apparent Terminal Elimination Half-life (t1/2)', 'timeFrame': '0 - 120 hours post-dose'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'keywords': ['HT-1', 'Tyrosinemia', 'Nitisinone', 'Bioavailability', 'Healthy Volunteer', 'Food-Effect'], 'conditions': ['Hereditary Tyrosinemia, Type I']}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to compare the bioavailability of the Test Product, Nitisinone 10 mg Tablet, under fasting and fed conditions (food-effect).', 'detailedDescription': 'The specific aim is to conduct a randomized, single dose, two-period crossover bioavailability study in at least 16 healthy male and female subjects at a single study center to evaluate the in vivo performance of Test Product, Nitisinone 10 mg Tablet, under fasting and fed conditions.\n\nThe study in healthy male and female volunteers is designed to establish a pharmacokinetic (PK) profile under fed and fasting conditions for the orally administered Test Product, Nitisinone 10 mg Tablets.\n\nA total of 20 healthy female and male volunteers (age 18 to 55 years old) will be entered into the study. Volunteers will be determined to be free of significant medical conditions as assessed by medical history, physical examination, and blood and urine tests. Volunteers will be randomly allocated to receive the Test Product under fasting or fed conditions.\n\nThere will be a minimum 23 calendar days washout between treatments. Blood samples will be collected at pre-dose (0 hours) and at 15 minutes, 30 minutes, 1 hour, 2 hours, 2 hours and 30 minutes, 3 hours, 3 hours and 30 minutes, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours, 72 hours, 96 hours and 120 hours post-dose (total: 21 samples per treatment period).'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT'], 'maximumAge': '55 Years', 'minimumAge': '18 Years', 'healthyVolunteers': True, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Healthy male and female subjects, 18 to 55 years (both inclusive) at signing of informed consent.\n* Body Mass Index (BMI) between 18.5 and 30 kg/m2 (inclusive).\n* Body mass not less than 50 kg.\n* Medical history, vital signs, physical examination, standard 12-lead electrocardiogram (ECG) and laboratory investigations must be clinically acceptable or within laboratory reference ranges for the relevant laboratory tests, unless the investigator considers the deviation to be irrelevant for the purpose of the study.\n* Non-smokers.\n* Females, if:\n\nOf childbearing potential, the following conditions are to be met:\n\n* Negative pregnancy test If this test is positive, the subject will be excluded from the study. In the rare circumstance that a pregnancy is discovered after the subject received IMP, every attempt must be made to follow her to term.\n* Not lactating\n* Abstaining from sexual activity (if this is the usual lifestyle of the subject) or must agree to use an accepted method of contraception, and agree to continue with the same method throughout the study Examples of reliable methods of contraception include non-hormonal intrauterine device, and barrier methods combined with an additional contraceptive method. In this study the concomitant use of hormonal contraceptives is NOT allowed. Other methods, if considered by the investigator as reliable, will be accepted.\n* Written consent given for participation in the study.\n* Subjects must be willing to consume the meal prescribed with administration of the IMP in full and within the required time.\n\nExclusion Criteria:\n\n* Evidence of psychiatric disorder, antagonistic personality, poor motivation, emotional or intellectual problems likely to limit the validity of consent to participate in the study or limit the ability to comply with protocol requirements.\n* Current alcohol use \\> 21 units of alcohol per week for males and \\> 14 units of alcohol per week for females.\n* Consumption of more than 5 cups of coffee (or equivalent amounts of caffeine) per day.\n* Regular exposure to substances of abuse (other than alcohol) within the past year.\n* Use of any medication, prescribed or over-the-counter or herbal remedies, within 2 weeks before the first administration of investigational medicinal product (IMP) except if this will not affect the outcome of the study in the opinion of the investigator.\n\nIn this study the concomitant use of hormonal contraceptives is NOT allowed.\n\n* Participation in another study with an experimental drug, where the last administration of the previous IMP was within 8 weeks (or within 10 elimination half-lives for chemical entities or 2 elimination half-lives for antibodies or insulin), whichever is the longer) before administration of IMP in this study, at the discretion of the investigator.\n* Treatment within the previous 3 months before the first administration of IMP with any drug with a well-defined potential for adversely affecting a major organ or system.\n* A major illness during the 3 months before commencement of the screening period.\n* History of hypersensitivity or allergy to the IMP or its excipients or any related medication.\n* History of bronchial asthma or any other bronchospastic disease.\n* History of convulsions.\n* History of porphyria.\n* Relevant history or laboratory or clinical findings indicative of acute or chronic disease, likely to influence study outcome.\n* Donation or loss of blood equal to or exceeding 500 mL during the 8 weeks before the first administration of IMP.\n* Diagnosis of hypotension made during the screening period.\n* Diagnosis of hypertension made during the screening period or current diagnosis of hypertension.\n* Resting pulse of \\> 100 beats per minute or \\< 40 beats per minute during the screening period, either supine or standing.\n* Positive testing for human immunodeficiency virus (HIV), Hepatitis B and Hepatitis C.\n* Positive urine screen for drugs of abuse. In case of a positive result the urine screen for drugs of abuse may be repeated once at the discretion of the investigator.\n* Positive urine screen for tobacco use.\n* Positive pregnancy test.\n* Female subjects that are pregnant or breastfeeding.\n* Difficulty in swallowing.\n* Any specific investigational product safety concern.\n* Vulnerable subjects, e.g. persons in detention.\n* Subjects with current keratopathy, or other clinically significant abnormalities found by slit-lamp examination (cataracts) at the discretion of the investigator.\n* Concomitant use of medications that are metabolized by CYP2C9 (ibuprofen, diclofenac and indomethacin).'}, 'identificationModule': {'nctId': 'NCT02750332', 'briefTitle': 'Bioavailability Food-Effect Study of an Oral Nitisinone Formulation to Treat Hereditary Tyrosinemia (HT-1)', 'organization': {'class': 'INDUSTRY', 'fullName': 'Cycle Pharmaceuticals Ltd.'}, 'officialTitle': 'A Single Center, Single-Dose, Open-Label, Randomized Study to Compare the Bioavailability of an Oral Test Formulation Containing Nitisinone 10 mg in at Least 16 Healthy Male and Female Subjects Under Fasting and Fed Conditions', 'orgStudyIdInfo': {'id': 'CT-002'}, 'secondaryIdInfos': [{'id': 'PXL225421', 'type': 'OTHER', 'domain': 'PAREXEL'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Treatment Sequence A (Fed) - B (Fasted)', 'description': 'Subjects will receive a single 10 mg tablet of Nitisinone in treatment period 1 under fed conditions, and 10 mg tablet of Nitisinone in treatment period 2 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.', 'interventionNames': ['Drug: Nitisinone']}, {'type': 'EXPERIMENTAL', 'label': 'Treatment Sequence B (Fasted) - A (Fed)', 'description': 'Subjects will receive a single 10 mg tablet of Nitisinone in treatment period 1 under fasting conditions, and 10 mg tablet of Nitisinone in treatment period 2 under fed conditions. Each treatment period will be separated by at least 23 calendar days of washout period.', 'interventionNames': ['Drug: Nitisinone']}], 'interventions': [{'name': 'Nitisinone', 'type': 'DRUG', 'description': 'A single oral dose of Nitisinone 10 mg Tablet will be administered.', 'armGroupLabels': ['Treatment Sequence A (Fed) - B (Fasted)', 'Treatment Sequence B (Fasted) - A (Fed)']}]}, 'contactsLocationsModule': {'locations': [{'zip': '9301', 'city': 'Bloemfontein', 'state': 'Free State', 'country': 'South Africa', 'facility': 'Bloemfontein Early Phase Clinical Unit, PAREXEL International (South Africa)', 'geoPoint': {'lat': -29.12107, 'lon': 26.214}}], 'overallOfficials': [{'name': 'André Nell', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': '+27 51 410 3046'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'UNDECIDED'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Cycle Pharmaceuticals Ltd.', 'class': 'INDUSTRY'}, 'collaborators': [{'name': 'Parexel', 'class': 'INDUSTRY'}], 'responsibleParty': {'type': 'SPONSOR'}}}}